Targeting the EGF Receptor for Ovarian Cancer Therapy

Ovarian carcinoma is the leading cause of death from gynecologic malignancy in the US. Factors such as the molecular heterogeneity of ovarian tumors and frequent diagnosis at advanced stages hamper effective disease treatment. There is growing emphasis on the identification and development of targeted therapies to disrupt molecular pathways in cancer. The epidermal growth factor (EGF) receptor is one such protein target with potential utility in the management of ovarian cancer. This paper will discuss contributions of EGF receptor activation to ovarian cancer pathogenesis and the status of EGF receptor inhibitors and EGF receptor targeted therapies in ovarian cancer treatment.

[1]  P. D. de Witte,et al.  Photocytotoxic action of EGF-PVA-Sn(IV)chlorin e6 and EGF-dextran-Sn(IV)chlorin e6 internalizable conjugates on A431 cells. , 1998, International journal of oncology.

[2]  Ching-Li Tseng,et al.  The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. , 2009, Biomaterials.

[3]  H. Hurwitz,et al.  Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors. , 2016, Journal of Clinical Oncology.

[4]  A. Frankel.  Immunotoxin therapy of cancer. , 1993, Oncology.

[5]  A. Citri,et al.  EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.

[6]  H. Herschman,et al.  Killing of cultured hepatocytes by conjugates of asialofetuin and EGF linked to the A chains of ricin or diphtheria toxin , 1982, Cell.

[7]  C. Muller,et al.  Phase I/II lapatinib plus carboplatin and paclitaxel in stage III or IV relapsed ovarian cancer patients , 2008 .

[8]  B. Rubino,et al.  The role of epithelial-mesenchymal transition in cancer pathology. , 2007, Pathology.

[9]  H. Burris,et al.  A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. , 2007, Gynecologic oncology.

[10]  H. Faulstich,et al.  Epidermal growth factor labeled beta-amanitin-poly-L-ornithine: preparation and evidence for specific cytotoxicity. , 1990, Biochemistry.

[11]  M. Kitajima,et al.  Epidermal growth factor receptor-dependent cytotoxic effect by an EGF—ribonuclease conjugate on human cancer cell lines -A trial for less immunogenic chimeric toxin- , 1996, Cancer Chemotherapy and Pharmacology.

[12]  G. Sauter,et al.  Epithelial growth factor receptor status in primary and recurrent ovarian cancer , 2006, Modern Pathology.

[13]  Thommey P. Thomas,et al.  Dendrimer-epidermal growth factor conjugate displays superagonist activity. , 2008, Biomacromolecules.

[14]  K. Berg,et al.  Photochemically Enhanced Gene Delivery of EGF Receptor-targeted DNA Polyplexes , 2004, Journal of drug targeting.

[15]  D. Toncheva,et al.  Tissue microarray analysis of EGFR and erbB2 copy number changes in ovarian tumors , 2004, International Journal of Gynecologic Cancer.

[16]  R. Kontermann,et al.  Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL). , 2009, Bioconjugate chemistry.

[17]  M. Seno,et al.  Molecular targeting for epidermal growth factor receptor expressed on breast cancer cells by human fusion protein , 1997, Breast cancer.

[18]  N. Auersperg,et al.  Serial propagation of human ovarian surface epithelium in tissue culture , 1988, Journal of cellular physiology.

[19]  Maoquan Chu,et al.  A convenient and adjustable surface-modified complex containing poly-L-glutamic acid conjugates as a vector for gene delivery , 2008, International journal of nanomedicine.

[20]  T. Park,et al.  Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus. , 2008, Biochemical and biophysical research communications.

[21]  D. Gilliland,et al.  Epidermal growth factor-toxin A chain conjugates: EGF-Ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic , 1980, Cell.

[22]  L. Gedda,et al.  Tumor-Cell Targeted Epidermal Growth Factor Liposomes Loaded with Boronated Acridine: Uptake and Processing , 2003, Pharmaceutical Research.

[23]  Yan Guo,et al.  Novel peptide ligand directs liposomes toward EGF‐R high‐expressing cancer cells in vitro and in vivo , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  Weibo Cai,et al.  Multimodality imaging of the HER-kinase axis in cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  R. Barth,et al.  Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents. , 2009, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[26]  M. Seno,et al.  The cytotoxicity of a conjugate composed of human epidermal growth factor and eosinophil cationic protein. , 2002, Anticancer research.

[27]  A. Secord,et al.  Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[28]  Jorma Isola,et al.  Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma , 2006, Journal of Molecular Medicine.

[29]  David J Riese,et al.  Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis , 2007, BioEssays : news and reviews in molecular, cellular and developmental biology.

[30]  H. Hollema,et al.  The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer , 2008, British Journal of Cancer.

[31]  T. Herzog,et al.  The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer , 2007, International Journal of Gynecologic Cancer.

[32]  H. Naora.  The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms , 2007, Expert Reviews in Molecular Medicine.

[33]  P. Malmström,et al.  EGF-receptor targeted liposomes with boronated acridine: Growth inhibition of cultured glioma cells after neutron irradiation , 2005, International journal of radiation biology.

[34]  N. Auersperg,et al.  The ovarian surface epithelium: simple source of a complex disease. , 2003, Minerva ginecologica.

[35]  R. Kalluri,et al.  Mechanisms of metastasis: Epithelial‐to‐mesenchymal transition and contribution of tumor microenvironment , 2007, Journal of cellular biochemistry.

[36]  R. Barth,et al.  Rat Brain Tumor Models to Assess the Efficacy of Boron Neutron Capture Therapy: A Critical Evaluation , 2004, Journal of Neuro-Oncology.

[37]  K. Skryabin,et al.  Antitumor Activity of Alpha Fetoprotein and Epidermal Growth Factor Conjugates in vitro and in vivo , 2000, Tumor Biology.

[38]  N. Feldman,et al.  Cytotoxic and Antitumor Activities of Doxorubicin Conjugates with the Epidermal Growth Factor and its Receptor-binding Fragment , 2002, Journal of drug targeting.

[39]  M. Conti,et al.  Role of the Epidermal Growth Factor Network in Ovarian Follicles the Physiology of Follicle Maturation and Ovulation , 2022 .

[40]  Karen D. Cowden Dahl,et al.  Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. , 2008, Cancer research.

[41]  K. Edwards,et al.  Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents. , 2002, Bioconjugate chemistry.

[42]  Ming-Jium Shieh,et al.  Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. , 2008, Biomaterials.

[43]  Molly Brewer,et al.  Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  J. Roth,et al.  The contribution of poly-L-lysine, epidermal growth factor and streptavidin to EGF/PLL/DNA polyplex formation , 1998, Gene Therapy.

[45]  M. Stack,et al.  Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression , 2008, Clinical & Experimental Metastasis.

[46]  A. S. Sobolev,et al.  Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At. , 2008, International journal of radiation oncology, biology, physics.

[47]  F. Uckun,et al.  Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[49]  G. Carpenter,et al.  ErbB receptors: new insights on mechanisms and biology. , 2006, Trends in cell biology.

[50]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[51]  D. Bowers.  Strokes among childhood brain tumor survivors. , 2009, Cancer treatment and research.

[52]  Sunkyu Kim,et al.  Validating cancer drug targets , 2006, Nature.

[53]  M. Stack,et al.  Microenvironmental regulation of ovarian cancer metastasis. , 2009, Cancer treatment and research.

[54]  John Mendelsohn,et al.  Epidermal growth factor receptor targeting in cancer. , 2006, Seminars in oncology.

[55]  Sabine Boeckle,et al.  Melittin analogs with high lytic activity at endosomal pH enhance transfection with purified targeted PEI polyplexes. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[56]  S. Steinberg,et al.  A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer , 2007, Cancer.

[57]  O. De Wever,et al.  Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[58]  Hans Skovgaard Poulsen,et al.  Mechanisms for oncogenic activation of the epidermal growth factor receptor. , 2007, Cellular signalling.

[59]  Robert Langer,et al.  Impact of nanotechnology on drug delivery. , 2009, ACS nano.

[60]  C. Nanni,et al.  Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[61]  I. Ben‐Ami,et al.  Novel function of ovarian growth factors: combined studies by DNA microarray, biochemical and physiological approaches. , 2006, Molecular human reproduction.

[62]  J. Segall,et al.  The great escape: when cancer cells hijack the genes for chemotaxis and motility. , 2005, Annual review of cell and developmental biology.

[63]  J. Carlsson,et al.  Uptake of a boronated epidermal growth factor-dextran conjugate in CHO xenografts with and without human EGF-receptor expression. , 1998, Anti-cancer drug design.

[64]  Ido Amit,et al.  Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy , 2007, Molecular systems biology.

[65]  W. Evans,et al.  In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[66]  Chun Xing Li,et al.  Targeting Doxorubicin to Epidermal Growth Factor Receptors by Site-Specific Conjugation of C225 to Poly(L-Glutamic Acid) Through a Polyethylene Glycol Spacer , 2003, Pharmaceutical Research.

[67]  M. P. Kirpichnikov,et al.  Targeting Phthalocyanines to Tumor Cells Using Epidermal Growth Factor Conjugates , 1999, Tumor Biology.

[68]  A. Oza,et al.  Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  van der Ate Zee,et al.  Prognostic factors in ovarian cancer: current evidence and future prospects , 2003 .

[70]  A. Takayanagi,et al.  Immunogene approach toward cancer therapy using erythrocyte growth factor receptor-mediated gene delivery. , 1996, Cancer gene therapy.

[71]  E. Hay.  EMT Concept and Examples from the Vertebrate Embryo , 2005 .

[72]  M. Wilchek,et al.  Indirect immunotargeting of CIS‐PT to human epidermoid carcinoma KB using the avidin‐biotin system , 1991, International journal of cancer.

[73]  M. Ohtsubo,et al.  Targeted in vivo delivery of therapeutic gene into experimental squamous cell carcinomas using anti-epidermal growth factor receptor antibody: immunogene approach. , 1998, Human gene therapy.

[74]  R. Taetle,et al.  Effects of anti-epidermal growth factor (EGF) receptor antibodies and an anti-EGF receptor recombinant-ricin A chain immunoconjugate on growth of human cells. , 1988, Journal of the National Cancer Institute.

[75]  Qiang Wang,et al.  ErbB receptors: from oncogenes to targeted cancer therapies. , 2007, The Journal of clinical investigation.

[76]  M. Moasser,et al.  The epidermal growth factor receptor family: Biology driving targeted therapeutics , 2008, Cellular and Molecular Life Sciences.

[77]  K. Berg,et al.  DNA polyplexes based on degradable oligoethylenimine-derivatives: combination with EGF receptor targeting and endosomal release functions. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[78]  J. Mendelsohn,et al.  Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. , 1989, Cancer research.

[79]  E. Wagner,et al.  Different strategies for formation of pegylated EGF-conjugated PEI/DNA complexes for targeted gene delivery. , 2001, Bioconjugate chemistry.

[80]  Zonghai Li,et al.  Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. , 2008, International journal of pharmaceutics.

[81]  S. Selvaggi,et al.  Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament , 2009, Archives of pathology & laboratory medicine.

[82]  M. Bracke,et al.  Epithelial-Mesenchymal Transitions in Human Cancer , 2005 .

[83]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[84]  Mitchel S Berger,et al.  Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. , 2008, Neuro-oncology.

[85]  Haeshin Lee,et al.  A receptor-mediated gene delivery system using streptavidin and biotin-derivatized, pegylated epidermal growth factor. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[86]  E. Wagner,et al.  Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice , 2002, Hepatology.

[87]  Jerry M Maniate,et al.  Targeting the EGFR pathway for cancer therapy. , 2006, Current medicinal chemistry.

[88]  David L Rimm,et al.  Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer , 2005, Clinical Cancer Research.

[89]  B. Vanderhyden,et al.  Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  R. Richards-Kortum,et al.  Oligonucleotide-coated metallic nanoparticles as a flexible platform for molecular imaging agents. , 2007, Bioconjugate chemistry.

[91]  W. Merlevede,et al.  Epidermal growth factor-mediated targeting of chlorin e6 selectively potentiates its photodynamic activity. , 2000, Cancer research.

[92]  K. Wester,et al.  Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression. , 2006, Journal of neuro-oncology.

[93]  Timothy A. Yap,et al.  Beyond chemotherapy: targeted therapies in ovarian cancer , 2009, Nature Reviews Cancer.

[94]  J. Roth,et al.  Epidermal growth factor mediated DNA delivery into lung cancer cells via the epidermal growth factor receptor. , 1996, Cancer gene therapy.

[95]  K. Berg,et al.  Photochemical enhancement of DNA delivery by EGF receptor targeted polyplexes. , 2008, Methods in molecular biology.

[96]  N. Shimizu,et al.  Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody. , 1989, Cancer research.

[97]  M. Hecking,et al.  The epidermal growth factor receptor: from development to tumorigenesis. , 2007, Differentiation; research in biological diversity.

[98]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[99]  P. Leung,et al.  Ovarian surface epithelium: biology, endocrinology, and pathology. , 2001, Endocrine reviews.

[100]  Tomoko Ito,et al.  Novel poly(ethylene glycol) derivatives with carboxylic acid pendant groups: synthesis and their protection and enhancing effect on non-viral gene transfection systems , 2003, Journal of biomaterials science. Polymer edition.

[101]  N. Shimizu,et al.  Ex vivo Delivery of Suicide Genes into Melanoma Cells Using Epidermal Growth Factor Receptor‐specific Fab Immunogene , 1999, Japanese journal of cancer research : Gann.

[102]  M. Stack,et al.  Activated epidermal growth factor receptor in ovarian cancer. , 2009, Cancer treatment and research.

[103]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[104]  N. Normanno,et al.  Epidermal growth factor receptor (EGFR) signaling in cancer. , 2006, Gene.

[105]  N. Auersperg,et al.  Normal ovarian surface epithelium. , 2002, Cancer treatment and research.

[106]  Park S. Nobel,et al.  Summary and Future Perspectives , 2004 .

[107]  A. Takayanagi,et al.  A novel gene delivery system using EGF receptor‐mediated endocytosis , 1994, FEBS letters.

[108]  Erez M. Bublil,et al.  The EGF receptor family : spearheading a merger of signaling and therapeutics , 2007 .

[109]  M. Seno,et al.  Mechanisms of the growth-inhibitory effect of the RNase-EGF fused protein against EGFR-overexpressing cells. , 2006, Anticancer research.

[110]  Laurie G Hudson,et al.  Role of polyethylene glycol integrity in specific receptor targeting of carbon nanotubes to cancer cells. , 2009, Nano letters.

[111]  H. Beug,et al.  Molecular requirements for epithelial-mesenchymal transition during tumor progression. , 2005, Current opinion in cell biology.

[112]  A. Baron,et al.  Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. , 2008, Biochimica et biophysica acta.

[113]  H. Murrieta,et al.  Effect of irradiation dose, storage time and temperature on the ESR signal in irradiated oat, corn and wheat. , 1996, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[114]  T. Hamilton,et al.  Identification of epidermal growth factor-responsive genes in normal rat ovarian surface epithelial cells. , 2003, Biochemical and biophysical research communications.

[115]  Ming Yao,et al.  Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.